Christopher Mehlin
Company: Link Immunotherapeutics
Job title: Chief Scientific Officer & Co-founder
Seminars:
Panel Discussion – Different Viewpoints of Bi & Multi Specifics in the Field 9:00 am
Comparing and contrasting CD3 bispecifics versus new T cell targets for a better understanding of the different avenues available Progression of the bispecific antibodies towards multi-specificity and moving from bi to tri to tetra specific antibodies Sharing thoughts on how to drive the cell therapy field into a new era of more accessible ‘curative’ therapiesRead more
day: Day One
Roundtable Discussion – Understanding Different Formats Behavior to Identify Which One Works Best 1:30 pm
Harnessing NK Cell in Cancer Therapies by Antibody-Based NK Cell Engager Therapeutics Clarifying how formats behave specifically in the system, NK/ Gamma-Delta/ Macrophages/ Immuno-cytokines Evolving opportunities within different targets and mechanisms of action to learn which is the best method Discussing a case study on blockers, agonist or antagonistRead more
day: Focus Day Track A - PM
Chair’s Opening Remarks 10:20 am
day: Pre-Conference Focus Day